RBC Capital defends Karyopharm Therapeutics (KPTI) amid 10pct premarket drop: 'We see upside potential'

March 24, 2026 9:19 AM

RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $23.00 price target on Karyopharm ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found